Currentblue cross blue shield - tennesseePolicy N/A

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

Defines coverage criteria for measurement of serum drug concentrations and anti-drug antibodies to guide management of biologic therapies, focusing primarily on inflammatory bowel disease (IBD) patients and specifying noncoverage for most other indications.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDocument that the patient has IBD and meets a covered scenario (end of induction, at least once during maintenance, end of induction for primary non-responders, or confirmed secondary loss of response) when requesting drug and/or antibody concentration testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

IBD-focusedCoverage targeted to

10 biologics listedNamed biologics listed

>=2 μg/mlInfliximab trough assoc.

458Randomized trial size

detectable onlyVedolizumab/ustekinumab stance

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

6 codesProcedure codes listed

Coverage Criteria for Therapeutic Drug Monitoring

IBD — Anti-TNF testing (covered)

Covered when ANY of the following (for individuals with IBD):

Anti-TNF therapies in IBD: Drug and/or antibody concentration testing for anti-TNF therapies meets coverage criteria in any of: (a) at the end of induction for all anti-TNFs; (b) at least once during maintenance therapy; (c) at the end of induction in primary non-responders; (d) for individuals with confirmed secondary loss of response.

From policy Indications and/or Limitations of Coverage.

IBD — Vedolizumab/ustekinumab testing (covered)

Covered when ANY of the following (for individuals with IBD receiving vedolizumab or ustekinumab):

Vedolizumab or ustekinumab in IBD: Drug and/or antibody concentration testing meets coverage criteria in: (a) at the end of induction in non-responders; (b) for individuals with confirmed secondary loss of response.

From policy Indications and/or Limitations of Coverage.

Not covered — Non-IBD and other situations

Non-IBD indications and other situations: For individuals with conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti-TNF therapies does not meet coverage criteria. For all other situations not addressed above, measurement of serum drug levels and/or antibodies does not meet coverage criteria for the listed drugs (adalimumab, certolizumab, etanercept, golimumab, infliximab, infliximab-dyyb, infliximab-abda, rituximab, ustekinumab, vedolizumab).

From Reimbursement Policy noncoverage list.

Appropriate scenarios for TDM (anti‑TNFs)

Consensus statements and guideline‑based scenarios where ordering drug/antibody concentration testing is appropriate:

Anti‑TNF TDM appropriateness: For anti‑TNF therapies it is appropriate to order drug/antibody concentration testing at the end of induction for responders, at least once during maintenance, in primary non‑responders at end of induction, and for confirmed secondary loss of response.see thresholds for drug‑specific concentrations

Consensus agreement reported across guideline statements (Papamichael et al.).

Vedolizumab and Ustekinumab

Agents with limited consensus for proactive monitoring:

Vedolizumab and Ustekinumab TDM: Proactive monitoring for vedolizumab and ustekinumab had low consensus for responders and routine maintenance; reactive monitoring for non-responders and confirmed secondary loss of response had higher agreement. Specific quantitative induction and maintenance targets are not established beyond presence of detectable drug.agent-specific thresholds limited or not established

Evidence weaker for proactive TDM with these agents (Papamichael et al.).

Certolizumab concentration target

Covered when ALL of the following are met:

Certolizumab maintenance target: During maintenance, the minimum trough concentration for certolizumab pegol for patients in remission should be 15 μg/mL.15 μg/mL

From guideline statement in policy.

Golimumab concentration targets

Covered when ALL of the following are met:

Golimumab induction target: Minimum drug concentration at week 6 for golimumab should be at least 2.5 μg/mL.2.5 μg/mL

From guideline statement in policy.

Golimumab maintenance target: During maintenance, the minimum trough concentration for golimumab for patients in remission should be greater than 1 μg/mL.>1 μg/mL

From guideline statement in policy.

Vedolizumab and Ustekinumab — limited evidence

Guidance / informational:

Vedolizumab and ustekinumab: Current data are emerging but insufficient to support specific induction or maintenance concentration targets for vedolizumab and ustekinumab beyond confirming that drug is detectable.detectable

From guideline statement in policy.

Testing for drug and/or antibody concentrations for anti‑TNF therapies in indications other than inflammatory bowel disease (for example, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria and may be denied. This exclusion also extends to measurement of serum drug levels or anti‑drug antibodies in clinical situations not explicitly listed as covered in this policy, including for the following agents: adalimumab, certolizumab, etanercept, golimumab, infliximab (and infliximab biosimilars), rituximab, ustekinumab, and vedolizumab.

The National Institute for Health and Care Excellence (NICE) concluded that while ELISA kits for therapeutic monitoring of TNF‑alpha inhibitors in Crohn's disease show promise, there is insufficient evidence to recommend their routine adoption. NICE recommends that ELISA testing be used only as part of research or data‑collection activities and similarly notes insufficient evidence to support routine ELISA use for rheumatoid arthritis.

For vedolizumab and ustekinumab the evidence is currently insufficient to define specific quantitative induction or maintenance concentration targets. Available guidance recommends only confirming the presence of drug (i.e., a detectable drug concentration) rather than applying firm numeric trough targets for clinical decisions.

Measurement of serum drug levels and/or anti‑drug antibodies for the listed biologic agents does not meet coverage criteria when requested for situations that are not specifically covered by this policy. Requests outside the covered IBD scenarios should be considered not medically necessary and may be denied.

Routine adoption of ELISA‑based therapeutic drug monitoring for TNF inhibitors is not currently supported by NICE because of limited evidence for clinical benefit. NICE specifies that ELISA testing should be limited to research and data collection until further evidence clarifies clinical effectiveness and appropriate use.

Procedure Codes and Drug Concentration Targets

Assay portfolios / vendor offeringsmixed

not specified

Laboratory assay portfolios (e.g., OptimAbs, Prometheus Anser, LabCorp DoseASSURE) for multiple biologics — company product listings rather than discrete CPT/HCPCS codes

Referenced procedure codesCPT

80145	Adalimumab.
80230	Infliximab.
80280	Vedolizumab.
80299	Quantitation of therapeutic drug, not elsewhere specified.
82397	Chemiluminescent assay.
84999	Unlisted chemistry procedure

inv-16: Infliximab trough concentration — key thresholds

Infliximab trough — general associationTrough ≥2 μg/mL is associated with increased probability of clinical remission and mucosal healing (some studies report ≥2.1 μg/mL for mucosal healing).

Infliximab post‑induction minimal target (study consensus)>3 μg/mL recommended as minimal trough post‑induction (week 14) per consensus statements.

Assay noteVariability between infliximab assays is unlikely to be clinically significant; specific assay cutoffs for antibodies vary by platform.

inv-17: Infliximab trough concentration (post‑induction and maintenance)

Post‑induction minimal trough>3 μg/mL (minimal trough at week 14).

Maintenance target for remission

Provider Actions, Documentation, and Billing Guidance

Prior Authorization

TDM May Trigger Utilization Review

Therapeutic drug monitoring (TDM) for biologic therapies (proactive or reactive) may trigger utilization review when results are used to guide management decisions (for example, at end of induction, during maintenance, or to evaluate primary nonresponse or secondary loss of response). Providers should document clinical rationale for testing and how measured drug and/or antibody levels will inform specific treatment actions (dose intensification, interval adjustment, switching agents, or class change).

TDM may prompt utilization review when used to direct clinical management (end of induction, maintenance checks, primary nonresponse, confirmed secondary loss of response).
Document why testing is being ordered and how results will change management (e.g., dose escalation vs switching biologics).

Documentation Required

Documentation for Covered IBD Testing

Documentation must support that the individual has inflammatory bowel disease (IBD) and meets one of the covered scenarios (e.g., end of induction for anti‑TNFs, at least once during maintenance, end of induction in primary non‑responders, or confirmed secondary loss of response). For vedolizumab and ustekinumab, documentation should support testing at end of induction in non‑responders or for confirmed secondary loss of response.

Background and Rationale

TNF inhibitors are widely used to treat inflammatory conditions but can elicit anti‑drug antibodies that reduce drug exposure and efficacy and may cause adverse effects. Therapeutic drug monitoring (measuring trough drug concentrations and anti‑drug antibodies) has the strongest evidence and guideline support in inflammatory bowel disease; for most other indications the literature is insufficient to support routine testing.

Definitions and Terminology

inv-38: Selected terminology

ADAbs / ATA / ATIADAbs = Anti-drug antibody status; ATA = Antibodies-to-adalimumab; ATI = Antibodies-to-infliximab.

TDM / TCTDM = Therapeutic drug monitoring; TC = Trough concentration.

LDT / HMSA abbreviationsLDTs = Laboratory-developed tests; HMSA = Homogeneous mobility shift assay.

inv-39: Proactive TDM

Proactive TDM definitionScheduled monitoring of serum drug levels and anti‑drug antibodies (e.g., at end of induction and at least once during maintenance) to maintain therapeutic concentrations and prevent loss of response.

When proactive TDM is considered appropriateFor anti‑TNF therapies, proactive TDM is appropriate after induction and at least once during maintenance per consensus statements.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

>3 μg/mL (maintenance trough associated with remission).

Higher target for mucosal healing>7 μg/mL associated with increased likelihood of mucosal healing.

When not to abandon infliximabInfliximab should generally not be abandoned for active disease unless concentrations are >10 μg/mL.

inv-18: Adalimumab concentrations

Adalimumab week 4 minimumMinimum drug concentration at week 4 should be at least 5 μg/mL.

Mucosal healing association>7 μg/mL associated with increased likelihood of mucosal healing.

Maintenance trough for remissionMaintenance trough should be >5 μg/mL for patients in remission.

When not to abandon adalimumabAdalimumab should generally not be abandoned for active disease unless concentrations are >10 μg/mL.

inv-19: Certolizumab pegol concentrations

Certolizumab week 6 minimumMinimum concentration at week 6 should be >32 μg/mL.

Maintenance trough for remissionDuring maintenance the minimum trough concentration for patients in remission should be 15 μg/mL.

inv-20: Golimumab concentrations

Golimumab week 6 (induction)Minimum drug concentration at week 6 should be ≥2.5 μg/mL.

Golimumab maintenance trough for remissionDuring maintenance the minimum trough for patients in remission should be >1 μg/mL.

inv-21: Certolizumab maintenance trough (remission)

Certolizumab maintenance trough (remission)15 μg/mL (minimum trough concentration during maintenance for patients in remission).

Evidence basisRecommendation supported by consensus statements (reported agreement 92%).

inv-22: Golimumab induction (week 6)

Golimumab induction (week 6) target≥2.5 μg/mL at week 6.

Consensus strengthRecommendation derived from panel consensus (92% agreement reported).

inv-23: Golimumab maintenance trough (remission)

Golimumab maintenance trough (remission)>1 μg/mL during maintenance for patients in remission.

Clinical contextTargets are consensus-based to guide TDM for induction and maintenance phases.

inv-24: Vedolizumab/ustekinumab — monitoring guidance

Vedolizumab/ustekinumab quantitative targetsNo specific induction or maintenance quantitative concentration targets recommended; only that drug should be detectable.

Evidence statusEmerging data suggest associations between concentrations and outcomes but are insufficient to set numeric thresholds.

Attach clinical notes confirming IBD diagnosis and the specific covered indication for testing (post‑induction, maintenance, primary nonresponse, or secondary loss of response).
Indicate prior therapies, current dosing schedule, and objective evidence of response or loss of response (symptoms, endoscopy, biomarkers).

Documentation Required

Documentation of Clinical Rationale and Measured Levels

Providers should include the clinical rationale and the measured drug and antibody levels in the record, and describe the intended management decision based on those values (for example: subtherapeutic trough → dose intensification; high‑titer antibodies → consider switching biologic or changing drug class). Quality‑improvement and outcomes data support post‑induction and reactive TDM to guide dose optimization in many IBD patients; include references to measured thresholds when used to support the plan.

Record the exact assay result (drug concentration in µg/mL, antibody presence/titer) and the date/time relative to dosing (trough vs non‑trough).
State the action to be taken if results meet predefined thresholds (e.g., specific trough cutoffs, presence of high‑titer antibodies).
If following an algorithm, note which algorithm or guideline informed the decision (include citation or local protocol).

Documentation Required

Testing to Inform Biologic Switching

Testing results are commonly used to inform whether to intensify dose, shorten dosing interval, switch to an alternative biologic, or change therapeutic class. Patients with high‑titer antidrug antibodies are more likely to be switched to another biologic, while low drug levels without antibodies may prompt dose optimization. Specify in documentation how results will inform switching or dose adjustments.

Document whether the plan is dose intensification, interval shortening, switching within class, or switching to a different mechanism of action.
Include evidence (antibody titer, drug trough) that supports the chosen strategy and anticipated monitoring after the change.

Documentation Required

Laboratory Test Validation

Laboratory‑developed tests (LDTs) used for therapeutic drug monitoring must be performed and validated in‑house under CLIA as high‑complexity tests. Note whether the assay is an LDT or an FDA‑cleared/approved kit, and ensure the lab validation status is documented.

Indicate the performing laboratory and whether the assay is an LDT; include CLIA certification information when available.
Confirm that the lab follows appropriate validation procedures for sensitivity, specificity, and reproducibility.

Billing Rule

Procedure Coding Reference and Coding Note

Procedure and billing codes are provided as general reference only. Use the performing laboratory’s billing guidance and payer requirements to determine the correct codes. Providers should include the clinical indication and test specifics on claims to support medical necessity.

Commonly referenced CPT/HCPCS codes include 80145 (adalimumab), 80230 (infliximab), 80280 (vedolizumab), 80299 (quantitation of therapeutic drug, NOS), 82397 (chemiluminescent assay), and 84999 (unlisted chemistry procedure).
Procedure codes in this policy are not exhaustive — confirm coding with the lab and payer prior to billing.

Note

Government Policy Precedence

If there is a conflict between this policy and any applicable government coverage (e.g., Medicare LCDs/NCDs or state Medicaid policies), the government policy will govern the coverage determination. Providers should check and cite the relevant LCD/NCD or state Medicaid policy when submitting requests for members covered under those programs.

Verify and cite applicable Local Coverage Determinations (LCDs), National Coverage Determinations (NCDs), or state Medicaid guidance when ordering or billing.
Follow government policy precedence for Medicare and Medicaid members; include the referenced policy number/date in the documentation when relevant.

inv-40: Reactive TDM

Reactive TDM definitionTesting performed in response to clinical nonresponse or loss of response to determine whether lack of efficacy is due to low drug levels or anti‑drug antibodies.

Guideline stanceAGA suggests reactive TDM to guide treatment changes in adults with active IBD (conditional recommendation, very low quality evidence).

inv-41: Laboratory‑developed test (LDT)

Laboratory-developed test (LDT)An assay developed and validated in-house and regulated by CMS under CLIA as high-complexity tests; LDTs are not FDA-approved/cleared but may be used clinically.